Bionomics (NASDAQ:BNOX) Receives Outperform Rating from William Blair

William Blair reissued their outperform rating on shares of Bionomics (NASDAQ:BNOX) in a research report released on Friday morning,RTT News reports.

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Bionomics in a research note on Thursday, August 1st.

Bionomics Trading Down 8.1 %

Shares of BNOX traded down $0.03 during mid-day trading on Friday, reaching $0.29. 419,169 shares of the stock traded hands, compared to its average volume of 3,067,924. The stock has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.64. Bionomics has a 12-month low of $0.18 and a 12-month high of $2.19.

Institutional Trading of Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Armistice Capital LLC acquired a new position in Bionomics Limited (NASDAQ:BNOX) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics at the end of the most recent reporting period. 15.90% of the stock is currently owned by hedge funds and other institutional investors.

Bionomics Company Profile

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.